BioSpace News Archive

Visiox Pharma, LLC. today announced the appointment of Cynthia Matossian , M.D. as Chief Medical Officer.

CNBX Pharmaceuticals Inc. (OTC-QB: CNBX) announced today that the Company’s patent application titled “COMPOSITION AND METHOD FOR TREATING CANCER WITH CANNABINOIDS” was filed on October 12, 2022 with the US Patent and Trademark Office (USPTO) and with the Israel Patent Office under a national phase of International Patent Application.

Global health services company Cigna Corporation (NYSE: CI) will release its third quarter 2022 financial results on Thursday, November 3, 2022, and will host a conference call the same day.

Carmine Therapeutics (“Carmine”), an EVX founded biotech company and emerging leader in non-viral gene therapies, today announced the first Closing of its Series A financing.

Medidata, a Dassault Systèmes company, has launched the Intelligent Trials Diversity Module to help improve the equity of clinical trials by providing site-level participant demographic data including race, sex, age, and ethnicity.

Lucy Therapeutics, Inc., a private biotech company developing proprietary mitochondrial-based small molecule therapies and biomarkers for neurological diseases, today announced promising preclinical data for multiple compounds in its lead program for Parkinson’s disease, during an oral presentation at the Michael J. Fox Foundation’s 14th annual Parkinson’s Disease Therapeutics Conference.

ACLIV, a Korean biotech company has obtained EPA approval. Its EPA registration number is 102332.

GoodRx (NASDAQ: GDRX), a leading consumer-focused digital healthcare platform, today announced a collaboration with Biogen (NASDAQ: BIIB) that aims to improve the patient and healthcare provider (HCP) experience when initiating a new specialty therapy.

Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended September 30, 2022, after the close of the stock market on Wednesday, October 26, 2022.

IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the “Company” or “IntelGenx”) today provided an update on its collaboration with its strategic partner, atai Life Sciences (NASDAQ:ATAI) (“atai”), for the development of novel formulations of pharmaceutical-grade psychedelics based on IntelGenx’s polymeric film technologies.